Journal of Cancer Science and Research
Open Access

Abstract

Improved survival with DOF regimen for the treatment of metastatic gastric adenocarcinoma

Pratik P Patil*, Ranga Rao Rangaraju, Waseem Abbas, Rudra Prasad Acharya and Archit Pandit

BACKGROUND: Patients with metastatic gastric adenocarcinoma have a relatively poor prognosis with a median survival of 6 months. The three-drug regimen of docetaxel, oxaliplatin and fluorouracil (DOF) has been shown to improve survival compared to the two-drug regimen of docetaxel and oxaliplatin with similar toxicity. However, there is no published Indian experience with this regimen.

AIM: The aim of this study was to evaluate the efficacy of DOF regimen in Indian patients.

MATERIAL AND METHODS: All patients with metastatic gastric cancer who were treated with DOF regimen at our tertiary care centre in North India from 2014 to 2018 were retrospectively reviewed. 15 patients received DOF regimen as docetaxel 60 mg/m2 and oxaliplatin 85 mg/m2 on Day 1, and continuous infusion 5-FU 750 mg/m2 over 48 hours with pegylated-granulocyte colony-stimulating factor support every 2 weeks until progression or unacceptable toxicity. The endpoints were overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) which were evaluated using Kaplan-Meier analysis.

RESULTS: Fifteen patients with a median age of 52 years were identified; 73% were males. Overall response rate was seen in 87% patients (complete response: 20%, partial response: 60%, stable disease: 7%) and progressive disease in 13%. With a median follow-up of 14 months, the median PFS was seven months and the median OS was 16 months from the start of therapy. 1-year PFS was 22%, and 1-and 2-year survival was 79% and 26%, respectively.

CONCLUSION: DOF regimen is an effective and feasible regimen in patients with metastatic gastric cancer and shows similar survival to historical regimens.

Published Date: 2023-01-27; Received Date: 2022-12-27